Novel Lactobacillus Fermentum LM1016 Strain, And Composition For Preventing Or Treating Cardiovascular Diseases

Abstract

The present invention relates to a novel strain of Lactobacillus fermentum LM1016 deposited with the Korean Culture Center of Microorganisms under accession number KCCM12468P. The novel strain of the present invention has an effect of treating or preventing cardiovascular diseases, obesity, fatty liver or diabetes mellitus. The present invention relates to a composition comprising the strain, and the composition may be used in a pharmaceutical product, a health functional food, a dairy product, a fermented product, a food additive and an animal feed and the like.

1 - 10 . (canceled) 
     
     
         11 . A method of treating cardiovascular diseases, obesity, diabetes mellitus or fatty liver diseases, the method comprising administering a  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) to a subject in need thereof. 
     
     
         12 . The method of  claim 11 , for treating cardiovascular diseases in a subject in need thereof. 
     
     
         13 . The method of  claim 12 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces the level of CRP (C-reactive protein), neutral fat or cholesterol, which is a risk factor for cardiovascular diseases. 
     
     
         14 . The method of  claim 11 , for treating obesity, diabetes mellitus or fatty liver disease in a subject in need thereof. 
     
     
         15 . The method of  claim 14 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces inflammation in subcutaneous fat. 
     
     
         16 . The method of  claim 11 , for treating obesity in a subject in need thereof, and wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces inflammation in subcutaneous fat. 
     
     
         17 . The method of  claim 14 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces the level of glucose, insulin or leptin in blood. 
     
     
         18 . The method of  claim 11 , for treating diabetes mellitus in a subject in need thereof, and wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces the level of glucose, insulin or leptin in blood. 
     
     
         19 . The method of  claim 14 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces the weight of the liver or the amount of neutral fat in the liver. 
     
     
         20 . The method of  claim 11 , for fatty liver disease in a subject in need thereof, and wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) reduces the weight of the liver or the amount of neutral fat in the liver. 
     
     
         21 . The method of  claim 11 , wherein the subject is a human. 
     
     
         22 . The method of  claim 11 , wherein the subject is a non-human animal. 
     
     
         23 . The method of  claim 11 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) is provided in a pharmaceutical composition. 
     
     
         24 . The method of  claim 11 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) is provided in a food composition. 
     
     
         25 . The method of  claim 21 , wherein the food composition is a health functional food, a dairy product, a fermented product or a food additive. 
     
     
         26 . The method of  claim 11 , wherein the  Lactobacillus   fermentum  LM1016 strain (KCCM12468P) is provided in an animal feed composition.